Here we report the expression cloning of cDNA encoding a putative opioid receptor from a human placenta cDNA library. Placental opioid receptors are of the K type. As the dynorphin opioid peptides are K-selective, a dynorphin ligand was used in an affinity-enrichment (panning) procedure to select transiently transfected COS-7 cells expressing K receptor binding sites. The cloned cDNA encodes a 440-residue protein of the seven-helix guanine nucleotidebinding protein (G-protein)-coupled receptor family. Ligand binding reveals a stereospecific site with typical opioid properties, which binds peptide and nonpeptide opioids with moderate affinity (Kd 100 nM) and which lacks the expected K selectivity. The deduced transmembrane domain is 93% identical to the homologous region of the human neuromedin K (neurokinin B) receptor, but the N-terminal and C-terminal sequences have many dissimilarities. The expressed receptor binds opioid ligands but not tachykinins; and under the same conditions, a cloned rat neuromedin K receptor binds tachykinins but not opioids. MATERIALS AND METHODS Vector and Library Construction. We used the pME18S vector (9), a high-copy-number small-vector [3.4 kilobases (kb)] plasmid with a strong promoter (10), suitable for constructing size-selected unidirectional cDNA libraries and for mammalian expression. Total RNA was isolated from fresh human placenta by guanidinium isothiocyanate extraction followed by centrifugation in cesium chloride (11), and poly(A)+ RNA was purified by using an oligo(dT)-cellulose column (Pharmacia). Synthesis of cDNA (12) was with a Promega kit. First-strand cDNA was synthesized by avian myeloblastosis virus reverse transcriptase with oligo(dT)-Not I primer-adapter [oligo(dT)15 containing the Not I site on its 5' end]. Second-strand cDNA was synthesized by using Escherichia coli DNA polymerase I and RNase H. After treatment with T4 DNA polymerase to blunt the ends, the doublestranded cDNA was ligated with Bst XI linker (Invitrogen) and T4 ligase at 14°C for 24 hr. After a treatment with Not I to create sticky ends, the cDNA was fractionated on 1% agarose gel by electrophoresis, and fractions > 1.5 kb were electroeluted to DE-81 ion-exchange paper (Whatman) and eluted with 1 M NaCl. After precipitation with ethanol, the cDNA was washed and unidirectionally inserted by T4 ligase into the BstXI-Not I sites ofpME18S. The resulting cDNA library had 1.4 x 106 independent colonies after transformation of DH5a competent E. coli by electroporation.
tical to the homologous region of the human neuromedin K (neurokinin B) receptor, but the N-terminal and C-terminal sequences have many dissimilarities. The expressed receptor binds opioid ligands but not tachykinins; and under the same conditions, a cloned rat neuromedin K receptor binds tachykinins but not opioids.
Saturable stereospecific binding of an opiate ligand was first demonstrated by one of us in 1971 (1) , and since then multiple opioid receptors have been characterized (2) (3) (4) (5) , but cloning has not yet been achieved to our knowledge. The cloning of an opioid-binding protein, OBCAM (6) , has been reported; but as it has no transmembrane domain, OBCAM seems not to be a receptor. For expression cloning of cDNA encoding the dynorphin (Dyn) (K opioid) receptor (7) by ligand binding, we turned to transient transfection of COS-7 cells and affinity enrichment (panning), followed by successive dilutions of plasmid pools. The cDNA library was derived from human placenta, a rich source of K receptors (8) .
MATERIALS AND METHODS Vector and Library Construction. We used the pME18S vector (9), a high-copy-number small-vector [3.4 kilobases (kb)] plasmid with a strong promoter (10) , suitable for constructing size-selected unidirectional cDNA libraries and for mammalian expression. Total RNA was isolated from fresh human placenta by guanidinium isothiocyanate extraction followed by centrifugation in cesium chloride (11) , and poly(A)+ RNA was purified by using an oligo(dT)-cellulose column (Pharmacia). Synthesis of cDNA (12) was with a Promega kit. First-strand cDNA was synthesized by avian myeloblastosis virus reverse transcriptase with oligo(dT)-Not I primer-adapter [oligo(dT)15 containing the Not I site on its 5' end]. Second-strand cDNA was synthesized by using Escherichia coli DNA polymerase I and RNase H. After treatment with T4 DNA polymerase to blunt the ends, the doublestranded cDNA was ligated with Bst XI linker (Invitrogen) and T4 ligase at 14°C for 24 hr. After a treatment with Not I to create sticky ends, the cDNA was fractionated on 1% agarose gel by electrophoresis, and fractions > 1.5 kb were electroeluted to DE-81 ion-exchange paper (Whatman) and eluted with 1 M NaCl. After precipitation with ethanol, the cDNA was washed and unidirectionally inserted by T4 ligase into the BstXI-Not I sites ofpME18S. The resulting cDNA library had 1.4 x 106 independent colonies after transformation of DH5a competent E. coli by electroporation.
Affinity Enrichment (Panning). In preparation for expression cloning, we had developed a set of modified (13) and chimeric (14) opioid peptides, the latter based on the structure of Dyn-32. Dyn-32 is the 17-residue DynA linked at its C terminus through Lys-Arg to DynB (15) . We had also raised a monoclonal antibody (mAb), 17.M, that recognized the C-terminal sequence of Dyn-32 (15) , leaving the opioid-active K-selective N-terminal domain free to interact with cellsurface receptors. These reagents were used for panning. COS-7 cells were transfected (16) as follows. Exponentially growing cells were plated (5 x 105 per 10-cm dish) in Dulbecco's modified Eagle's medium (DMEM) with 10o fetal calf serum (FCS). After 24 hr at 37°C in a 5% C02/95% air incubator, cells were washed twice with Iscove's modified Dulbecco's medium (IMDM), which contains L-glutamine and 25 mM Hepes (pH 7.4). Plasmid DNA [10 ,ug, purified by CsCl gradient centrifugation (11) ], DEAE-dextran (Mr 500,000, 0.2 mg/ml; Pharmacia), and chloroquine (100 ,uM) were mixed in 4 ml of IMDM and added to the dish, which was returned to the incubator for 5 hr. The cells were washed with IMDM and then with DMEM containing 5% FCS and were cultured in 10 ml of DMEM with 10% FCS for 3 days in the incubator.
The panning procedure itself was modified from Seed and Aruffo (17 saturation with a Kd of 87 nM (Fig. la) . Competition curves for both U-50488 and DynA-(1-13) yielded IC50 values (here equivalent to K,) of about 100 nM (Fig. lb) . The maximum reduction in binding by competition was approximately equal to the increment in binding due to transfection.
Competition results obtained with various ligands are shown in Fig. 2 . U-50488 gave near-maximal competition, and DynA-(1-13) competed about as well, but des-Tyr1-Proc. Natl. Acad. Sci. USA 89 (1992) DynA-(1-13) did not compete at all. Levorphanol (a A-opioid receptor-selective morphinan) competed, but its (+)-enantiomer dextrorphan (21) GCCCCGACCGCGTCCCCGTCCCCGGCCCCGTCGTGGACGCCCTCGCCGCGCCCCGGCCCC A P T A S Pt S P A P S W T P S P R P G P S A L G L : : : : : : U-63639 (IL-selective) and U-63640 (K-selective) (19) competed equally well.
Sequence Analysis. Fig. 3a shows the nucleotide and deduced amino acid sequence of hK1R cDNA and also of human NK receptor (hNKR; see below). In hK1R the insert of 4839 base pairs is followed by a poly(A) tract of 22 nucleotides. A long open reading frame after the first ATG encodes a protein of 440 residues (including the methionine) and calculated Mr of 49,422. The initial ATG (in CCCATGG) meets the Kozak consensus criterion (ACCATGG) (24) only moderately well; as the insert has no upstream in-frame stop codon, additional 5' coding sequence cannot be excluded. Fig. 3b shows the hydrophobicity analysis according to Kyte and Doolittle (23) . No signal sequence is present. Seven hydrophobic segments are evident, each long enough to form a membrane-spanning a-helix. These are placed in Fig. 3a according to the assignments for the tachykinin receptors (22) (see below), but additional flanking hydrophobic residues could have been included in all but transmembrane domains TM-3 and TM-4. In the N-terminal domain are two potential N-glycosylation sites, at amino acid residues 7 and 24. Cysteine residues occur in the first and second extracellular loops. In the C-terminal cytoplasmic tail, 27% of the residues are serine or threonine, suggesting possible regulation by protein kinases.
A search of the nucleic acid data bases revealed that the greatest similarity of hK1R was to receptors of the 7-helix family and especially to the rat NK receptor (rNKR), with 79% identity of the deduced protein sequences (three gaps). S. Nakanishi (Kyoto University) provided the rat clone (rNKR-CDM8) (25) , which was expressed in COS-7 cells.
Untransfected cells bound radiolabeled eledoisin hardly at all, whereas cells transfected with rNKR (but not hK1R) bound it very well (Table 1) . Radiolabeled Fig. 2 ).
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universal requirement for recognition of opioid peptides by opioid receptors. Therefore, it is significant that whereas DynA-(1-13) binds, its des-Tyr' derivative does not. (iii) Stereoselectivity is a feature of all known opioid receptors. The site expressed here is stereoselective, as revealed by the contrast between levorphanol and its enantiomer dextrorphan. (iv) Binding and functional behavior ofopioid receptors depend on coupling to a guanine nucleotide-binding protein (G protein), probably G, or Go (26) . It is significant, therefore, that the hydropathy plot here reveals a seven-helix structure, typical of receptors coupled to G proteins.
As a K-receptor-selective peptide ligand was used for panning, and as human placenta (source of the cDNA library) contains chiefly K receptors, we had expected to find typical K-receptor affinity (low nanomolar range) and also a preference (by at least 1 order of magnitude) for K-selective over puand 6-selective ligands. Thus, the observed affinity (2 orders of magnitude lower) and the poor selectivity of the expressed receptor were unexpected. There are five possible explanations. (i) As there is no stop codon upstream of the first ATG, a 5' coding sequence that makes a major contribution to affinity and selectivity could be missing. (ii) The correct G protein could be missing from the COS-7 cells, as found recently with a secretin receptor, which also belongs to the seven-helix family (27) . As the binding affinity in our experiments was unchanged in washed membrane preparations, a high cytosolic GTP concentration (well known to reduce binding affinity) (26) could not be responsible. (iii) An accessory protein other than a G-protein could be required for high-affinity binding and selectivity. More than a single polypeptide is sometimes required for high-affinity binding [e.g., interleukin 2 receptor (28)], but this has not been found for any G-protein-coupled receptor. (iv) A posttranslational modification could be needed for high-affinity binding but not carried out by COS-7 cells. It is noteworthy that there are two potential glycosylation sites in the extracellular N-terminal domain of the deduced sequence. (v) This opioid receptor is actually of a novel type, which does not discriminate among the classical type-selective ligands. A nonselective opioid receptor has been described (29) , but it has very high affinity for ju, K, and 8 ligands.
That a receptor with opioid binding properties should be a member of the tachykinin receptor family is interesting from an evolutionary standpoint. The similarity to hNKR also poses the question of what residues are responsible for ligand recognition. S. Nakanishi kindly informed us in advance of publication of the deduced amino acid sequence of hNKR (22) . The comparison is shown in Fig. 3a . Overall, there is 81% sequence identity (with three gaps), but the distribution of identical and nonidentical residues is very uneven.
Throughout the central transmembrane region the sequences are 93% identical (no gaps), and the cytoplasmic C-terminal tails are 74% identical (no gaps). The extracellular N-terminal domains differ greatly (39% identical, three gaps). Therefore, we suggest that the very different ligand binding selectivities of NKR and hK1R are determined in large part by the extracellular N-terminal domains, which are substantially different in the two receptors. Furthermore, hNKR and rNKR have three and four potential glycosylation sites, respectively, as compared with two in hK1R. This model is consistent with thyrotropin and luteinizing hormone receptors (30) as well as tachykinin receptors (22) . That ligands of seven-helix receptors bind in a pocket in the membrane was deduced from mutagenesis studies with small nonpeptide ligands (31) . For recognition of the extended pharmacophore of a peptide, the N-terminal extracellular domain of the receptor may be required. However, this hypothesis would not resolve the long-standing problem of how extended opioid peptides and compact opioid nonpeptides are recognized by the same binding site.
A final caveat is in order. Two segments of the coding sequence (beginning at nucleotides 18 and 585) contain alternative long open reading frames encoding 188 and 171 amino acids, respectively. Remote as the possibility may be in view of the multiple redundancies in our sequencing strategy, it is nevertheless conceivable that one or two nucleotides were missed, shifting the reading frame and resulting in a completely different deduced protein sequence. Analogous cases are known (32, 33) . However, the hydropathy plot for other reading frames of hK1R gives no indication of multiple transmembrane helixes.
